The latest price of mavacamten in 2025 and comparison of selling prices in domestic and foreign markets

Mavacamten is a new oral targeted drug used to treat hypertrophic cardiomyopathy (HCM). It can improve patients' cardiac function and exercise tolerance by inhibiting excessive increase in myocardial contractility. In 2025, Mavakaita Capsules will be launched in China and included in the medical insurance system, which means that eligible patients can enjoy partial reimbursement when purchasing it in the hospital, reducing their financial burden. However, due to differences in regional medical insurance policies, patients still need to consult their local hospital or pharmacy for specific reimbursement ratios and out-of-pocket amounts.

In the domestic market, the price of the European version of the original drug of Mavakatai Capsules ranges from about RMB 20,000 to more than 50,000 yuan, while the price of the American version of the original drug is even higher, about RMB 60,000 per box. Due to the high price, patients need to strictly follow the doctor's instructions when taking medication, and reasonably arrange medication according to the medical insurance reimbursement policy to ensure continuity of treatment and affordability. Doctors usually develop individualized medication plans based on the patient's condition, cardiac function indicators, and previous treatments.

In overseas markets, in addition to the original drug, generic versions of Mavaceta have also appeared. Taking the Laos market as an example, the price of the generic drug of Mavakatai produced by Lucius Company is only more than 1,000 yuan, which is much cheaper than the original drug. At the same time, the drug ingredients are basically the same as the original drug, providing a feasible choice for patients with limited financial conditions. Although generic drugs are cheap, patients still need to purchase them through formal channels to ensure drug quality and medication safety.

Overall, Mavakatai has been launched in China and is included in medical insurance, providing financial support to patients. At the same time, the price of generic drugs in overseas markets is more affordable. When choosing purchasing channels, patients should comprehensively consider medical insurance reimbursement, drug accessibility, price and doctor's advice to ensure continuity, safety and optimal efficacy of treatment.

Reference materials:https://www.drugs.com/